COVAX: Ensuring global equitable access to COVID-19 vaccines

With a fast-moving pandemic, no one is safe, unless
everyone is safe

What is COVAX

CEPI logo Gavi logo WHO logo

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

Why we need COVAX

Developing a vaccine against COVID-19 is the most pressing challenge of our time - and nobody wins the race until everyone wins.

The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.

What COVAX offers

population Doses for at least 20% of countries' populations
Vial Diverse and actively managed portfolio of vaccines
Box Vaccines delivered as soon as they are available
Pandemic End the acute phase of the pandemic
Money Rebuild economies

PRESS RELEASE

92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC

Credit: Gavi/2015/GMB Akash.

31 July 2020 – Press release

OPINION

The Fastest Way Out of the Pandemic
 

JEAN-PHILIPPE KSIAZEKAFP via Getty Images_coronavirusvaccinevials

15 July 2020 – Opinion

PRESS RELEASE

More than 150 countries engaged in COVID-19 vaccine global access facility

Pexels

15 July 2020 – Press release

ARTICLE

What is the COVAX pillar, why do we need it and how will it work?
 

Gavi/2020/Benedikt v.Loebell.

26 June 2020 – Article

Act Now. Act Together. Act boldly to end Covid-19.

Why we need to build  manufacturing capacity now

  1. Produce early doses to support clinical studies
  2. Scale up processes to industrial scale before clinical trials begin
  3. Scale-out products in different countries to expand capacity
  4. Stockpile vaccines in bulk in anticipation of dose level definition
  5. Anticipate projects failing during clinical development
  6. Repurpose facilities for successful products, if needed

All COVAX related documents

Gavi Covax AMC: an investment opportunity

Building upon two decades of experience in accelerating the availability of billions of doses of vaccines, Gavi is launching an investment opportunity: the Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC).

Subscribe to our newsletter